Skip to main content
Editas Medicine, Inc. logo

Editas Medicine, Inc. — Investor Relations & Filings

Ticker · EDIT ISIN · US28106W1036 LEI · 5299000AON4Q9NT2JE42 US Professional, scientific and technical activities
Open in API
Filings indexed 679 across all filing types
Latest filing 2026-05-26 Capital/Financing Update
Country US United States of America
Listing US EDIT

About Editas Medicine, Inc.

https://www.editasmedicine.com/

Editas Medicine, Inc. is a clinical-stage genome editing company focused on developing transformative medicines for serious diseases using CRISPR technology. The company's mission is to discover, develop, and commercialize durable, precision genomic therapies that can correct the underlying genetic causes of various conditions. Its proprietary platform enables the precise revision, removal, or replacement of DNA. Editas Medicine's research and development pipeline is concentrated on creating both in vivo (in-body) and ex vivo (out-of-body) gene-edited medicines to treat a broad class of diseases, with a focus on rare genetic disorders.

Recent filings

Filing Released Lang Actions
424B5
Capital/Financing Update Classification · 91% confidence The document is a Securities and Exchange Commission (SEC) 424(b)(5) prospectus supplement and accompanying prospectus detailing an offering of 55,555,556 shares of common stock and warrants, including pricing, underwriting, risk factors, and other financing terms. This is not a financial report (10-K, interim report) or an earnings release, but a full offering prospectus for raising capital. It clearly pertains to the company’s fundraising and capital structure changes (an equity financing). Therefore, it should be classified as a Capital/Financing Update.
2026-05-26 English
FORM 8-K
Capital/Financing Update Classification · 92% confidence The document is a SEC Form 8-K Current Report announcing the entry into a material definitive agreement (an underwriting agreement for a public offering of common stock and warrants). It details the terms of the offering, expected net proceeds, closing conditions, and related exhibits. This constitutes a capital/financing update rather than a full annual or interim report, insider transaction, or other category. Therefore, the most appropriate classification is Capital/Financing Update (CAP).
2026-05-26 English
FORM 8-K
Capital/Financing Update Classification · 87% confidence The document is a Form 8-K (a current report) by Editas Medicine disclosing that it is suspending and terminating the prospectus supplement for its “at-the-market” sales agreement with TD Cowen, and summarizing aggregate shares sold under that financing program. This is an update on the company’s capital raising/financing activities rather than a broader annual or interim report or simple regulatory notice. Therefore, it fits the “Capital/Financing Update” category (CAP).
2026-05-26 English
424B5
Share Issue/Capital Change Classification · 95% confidence The document is clearly a SEC Form 424B5 “Prospectus Supplement” combined with a Prospectus detailing the terms of a new securities offering, including “The Offering,” “Use of Proceeds,” “Description of Securities,” and underwriting arrangements. It is not an annual, interim report, earnings release, or governance document, but rather the formal notice and terms for issuing new shares to raise capital. Under our taxonomy, announcements of new share issuances and capital structure changes map to “Share Issue/Capital Change” (SHA).
2026-05-26 English
FORM 8-K
Regulatory Filings Classification · 91% confidence The document is a Current Report on Form 8-K filed with the U.S. SEC under the Exchange Act. It furnishes a press release under Item 7.01 (Regulation FD Disclosure) and describes other events under Item 8.01 (preclinical data presentation and forward‐looking statements). This is a regulatory filing and does not itself constitute an earnings release, proxy solicitation, or annual/interim report. As there is no bespoke category for Form 8-Ks, it falls into the general “Regulatory Filings” category (RNS).
2026-05-26 English
8-K
Regulatory Filings Classification · 9% confidence The document is a Form 8-K “Current Report” filed under the Securities Exchange Act, reporting a press release (Regulation FD Disclosure) and other event details. It does not contain full financial statements or earnings metrics, nor does it announce dividends, management changes, M&A, or other specific categories. As a general regulatory current report, it falls under the fallback category “Regulatory Filings” (RNS).
2026-05-14 English

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.